Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 15/20 | 0.52 |
| ▸ | PARP1 | P09874 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.42 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.39 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.39 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.39 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.39 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.39 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.39 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL274986 | 0.90 | NR1H4 (0.66) | NR1H4PARP1KCNH2KDM4EALDH1A1 | |
| SCHEMBL275056 | 0.82 | NR1H4 (0.68) | NR1H4PARP1 | |
| SCHEMBL328087 | 0.82 | NR1H4 (0.58) | NR1H4KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL13284304 | 0.80 | NR1H4 (0.76) | NR1H4KCNH2 | |
| SCHEMBL273500 | 0.76 | NR1H4 (0.73) | NR1H4 | |
| SCHEMBL29881430 | 0.76 | NR1H4 (0.73) | NR1H4 | |
| SCHEMBL275440 | 0.76 | NR1H4 (0.64) | NR1H4KCNH2 | |
| SCHEMBL15526741 | 0.75 | NR1H4 (0.58) | NR1H4KCNH2 | |
| SCHEMBL5732451 | 0.74 | NR1H4 (0.52) | NR1H4ALDH1A1 | |
| SCHEMBL1968461 | 0.74 | NR1H4 (0.82) | NR1H4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8133992-B2 | Azepinoindole and pyridoindole derivatives as pharmaceutical agents | EXELIXIS, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| EP-1532153-B1 | AZEPINOINDOLE AND PYRIDOINDOLE DERIVATIVES AS PHARMACEUTICAL AGENTS | X CEPTOR THERAPEUTICS INC (US) | 2012-02-29 | — | — | EP | disclosed |
| US-20090326218-A1 | Azepinoindole and Pyridoindole Derivatives as Pharmaceutical Agents | EXELIXIS, INC. (US) | 2009-12-31 | — | — | US | disclosed |
| US-7595311-B2 | Modulating active of receptors; therapy prevention of disease such aas symthrome X, antidiabetic agents, insulin resistance, hypoglycemic agents | EXELIXIS, INC. (US) | 2009-09-29 | — | — | US | disclosed |
| US-7485634-B2 | Azepinoindole and pyridoindole derivatives as pharmaceutical agents | EXELIXIS, INC. (US) | 2009-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326218-A1 | Azepinoindole and Pyridoindole Derivatives as Pharmaceutical Agents | HTR5A, MTNR1A, PTGDR | NR1H4 268/4885PARP1 3420/4885KCNH2 2762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.